Popoli Patrizia, Blum David, Martire Alberto, Ledent Catherine, Ceruti Stefania, Abbracchio Maria P
Department of Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
Prog Neurobiol. 2007 Apr;81(5-6):331-48. doi: 10.1016/j.pneurobio.2006.12.005. Epub 2007 Jan 9.
The aim of this review is to summarize and critically discuss the complex role played by adenosine A(2A) receptors (A(2A)Rs) in Huntington's disease (HD). Since A(2A)Rs are mainly localized on the neurons, which degenerate early in HD, and given their ability to stimulate glutamate outflow and inflammatory gliosis, it was hypothesized that they could be involved in the pathogenesis of HD, and that A(2A)R antagonists could be neuroprotective. This was further sustained by the demonstration that A(2A)Rs and underlying signaling systems undergo profound changes in cellular and animal models of HD. More recently, however, the equation A(2A) receptor blockade=neuroprotection has appeared too simplistic. First, it is now definitely clear that, besides mediating 'bad' responses (for example, stimulation of glutamate outflow and excessive glial activation), A(2A)Rs also promote 'good' responses (such as trophic and antinflammatory effects). This implies that A(2A)R blockade results either in pro-toxic or neuroprotective effects according to the mechanisms involved in a given experimental model. Second, since HD is a chronically progressive disease, the multiple mechanisms involving A(2A)Rs may play different relative roles along the degenerative process. Such different mechanisms can be influenced by A(2A)R activation or blockade in different ways, even leading to opposite outcomes depending on the time of agonist/antagonist administration. The number, and the complexity, of the possible scenarios is further increased by the influence of mutant Huntingtin on both the expression and functions of A(2A)Rs, and by the strikingly different effects mediated by A(2A)Rs expressed by different cell populations within the brain.
本综述的目的是总结并批判性地讨论腺苷A(2A)受体(A(2A)Rs)在亨廷顿舞蹈病(HD)中所起的复杂作用。由于A(2A)Rs主要定位于HD早期发生退化的神经元上,并且鉴于其刺激谷氨酸外流和炎症性胶质细胞增生的能力,人们推测它们可能参与HD的发病机制,且A(2A)R拮抗剂可能具有神经保护作用。HD细胞和动物模型中A(2A)Rs及其潜在信号系统发生深刻变化的证据进一步支持了这一推测。然而最近,A(2A)受体阻断=神经保护这一说法显得过于简单。首先,现在已经明确,除了介导“不良”反应(例如刺激谷氨酸外流和过度的胶质细胞激活)外,A(2A)Rs还能促进“良好”反应(如营养和抗炎作用)。这意味着根据给定实验模型中涉及的机制,A(2A)R阻断会产生促毒性或神经保护作用。其次,由于HD是一种慢性进行性疾病,涉及A(2A)Rs的多种机制在退化过程中可能发挥不同的相对作用。这些不同的机制可能以不同方式受到A(2A)R激活或阻断的影响,甚至根据激动剂/拮抗剂给药时间的不同导致相反的结果。突变型亨廷顿蛋白对A(2A)Rs表达和功能的影响,以及大脑中不同细胞群体表达的A(2A)Rs介导的显著不同效应,进一步增加了可能情况的数量和复杂性。